NO20090594L - 3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander - Google Patents
3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorliganderInfo
- Publication number
- NO20090594L NO20090594L NO20090594A NO20090594A NO20090594L NO 20090594 L NO20090594 L NO 20090594L NO 20090594 A NO20090594 A NO 20090594A NO 20090594 A NO20090594 A NO 20090594A NO 20090594 L NO20090594 L NO 20090594L
- Authority
- NO
- Norway
- Prior art keywords
- dione
- chemokine receptor
- receptor ligands
- cxc chemokine
- cyclobutene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
Abstract
Det beskrives nye syklobutendion-forbindelser 1 til 18 omfattende en syklobutendionring, en substituert fenylring, og en -CH(C2H5)-furangruppe. Både fenylringen og -CH(C2H5)-furangruppen er bundet til syklobutendionringen gjennom en -NH- gruppe. Det beskrives også anvendelse av forbindelser I til 18 for fremstilling av et medikament til behandling av kjemokin-formidlede sykdommer (for eksempel kreft, COPD, akutt og kroniske inflammasjonslidelser, psoriasis, systisk fibrose og astma).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81954106P | 2006-07-07 | 2006-07-07 | |
PCT/US2007/015671 WO2008005570A1 (en) | 2006-07-07 | 2007-07-05 | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20090594L true NO20090594L (no) | 2009-03-30 |
Family
ID=38654612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20090594A NO20090594L (no) | 2006-07-07 | 2009-02-06 | 3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander |
Country Status (20)
Country | Link |
---|---|
US (1) | US20080045489A1 (no) |
EP (1) | EP2041107A1 (no) |
JP (1) | JP2009542700A (no) |
KR (1) | KR20090028811A (no) |
CN (1) | CN101511809A (no) |
AR (1) | AR061829A1 (no) |
AU (1) | AU2007269572A1 (no) |
BR (1) | BRPI0713559A2 (no) |
CA (1) | CA2657051A1 (no) |
CL (1) | CL2007001969A1 (no) |
CO (1) | CO6150138A2 (no) |
EC (1) | ECSP099042A (no) |
IL (1) | IL196335A0 (no) |
MX (1) | MX2009000123A (no) |
NO (1) | NO20090594L (no) |
PE (1) | PE20080553A1 (no) |
RU (1) | RU2009103999A (no) |
TW (1) | TW200813033A (no) |
WO (1) | WO2008005570A1 (no) |
ZA (1) | ZA200900110B (no) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA95298C2 (ru) * | 2006-07-07 | 2011-07-25 | Бьёрингер Ингельхайм Интернациональ Гмбх | Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств |
JP2010531850A (ja) * | 2007-07-02 | 2010-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物 |
CL2008001943A1 (es) * | 2007-07-02 | 2009-09-11 | Boehringer Ingelheim Int | Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. |
US8519168B2 (en) * | 2007-07-03 | 2013-08-27 | Merck Sharp & Dohme Corp. | Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |
WO2009005802A1 (en) * | 2007-07-05 | 2009-01-08 | Schering Corporation | Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |
EP2252327A2 (en) * | 2007-12-04 | 2010-11-24 | Schering Corporation | Methods of treating copd |
UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
PE20110294A1 (es) | 2008-09-29 | 2011-05-26 | Boehringer Ingelheim Int | Compuestos heterociclicos como inhibidores de enzimas de senal especifica |
WO2010063802A1 (en) * | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
EP2552905B1 (en) | 2010-03-26 | 2016-10-05 | Boehringer Ingelheim International GmbH | B-Raf kinase inhibitors |
WO2011117382A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | Pyridyltriazoles |
FR2961695B1 (fr) * | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | Utilisation de composes dans le traitement ou la prevention de troubles cutanes |
US8710055B2 (en) | 2010-12-21 | 2014-04-29 | Boehringer Ingelheim International Gmbh | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors |
HUE035751T2 (hu) | 2011-09-02 | 2018-08-28 | Novartis Ag | Gyulladásgátló szubsztituált ciklobuténdion vegyület kolinsó |
FR2981934B1 (fr) | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
WO2016194869A1 (ja) | 2015-05-29 | 2016-12-08 | 生化学工業株式会社 | グリコサミノグリカン誘導体とケモカイン受容体活性調節材とを含む組成物 |
TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Cxcr2抑制劑 |
TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
CA3087701A1 (en) | 2018-01-08 | 2019-07-11 | Chemocentryx, Inc. | Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2 |
CN116874466A (zh) | 2018-09-21 | 2023-10-13 | 辉瑞公司 | 用作ccr6抑制剂的n-取代二氧代环丁烯基氨基-3-羟基-吡啶甲酰胺 |
CN109879854A (zh) * | 2019-03-25 | 2019-06-14 | 河南湾流生物科技有限公司 | 一种具有抗氧化作用的环丁烯酮类化合物及其制备方法 |
CN111329857B (zh) * | 2020-04-10 | 2022-10-11 | 青岛大学附属医院 | 一种氟苯甲酰胺衍生物注射液及其抗乳腺癌应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS214745B2 (en) * | 1976-08-28 | 1982-05-28 | Huels Chemische Werke Ag | Shaped and non-shaped products from plastic materials |
JPS60255756A (ja) * | 1984-06-01 | 1985-12-17 | Ikeda Mohandou:Kk | アミノアルキルフエノキシ誘導体 |
US5206252A (en) * | 1992-05-08 | 1993-04-27 | American Home Products Corporation | Thiadiazolyl-amino derivatives of benzopyrans and indanes |
US5506252A (en) * | 1993-11-17 | 1996-04-09 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
US5354763A (en) * | 1993-11-17 | 1994-10-11 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
US5466712A (en) * | 1994-11-04 | 1995-11-14 | American Home Products Corporation | Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones |
US6709594B2 (en) * | 1995-11-02 | 2004-03-23 | Dh20, L.L.C. | Method for treating waste-activated sludge using electroporation |
TR199901710T2 (xx) * | 1997-01-23 | 1999-09-21 | Smithkline Beecham Corporation | IL-8 resept�r antagonistleri. |
US5840764A (en) * | 1997-01-30 | 1998-11-24 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
AR015425A1 (es) * | 1997-09-05 | 2001-05-02 | Smithkline Beecham Corp | Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion |
US6376555B1 (en) * | 1998-12-04 | 2002-04-23 | American Home Products Corporation | 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers |
US6420396B1 (en) * | 1998-12-16 | 2002-07-16 | Beiersdorf Ag | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
US20030204085A1 (en) * | 2001-02-02 | 2003-10-30 | Taveras Arthur G. | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists |
US7132445B2 (en) * | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
US20040106794A1 (en) * | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
SK287598B6 (sk) * | 2001-04-16 | 2011-03-04 | Schering Corporation | 3,4-Disubstituované cyklobutén-1,2-dióny, farmaceutický prostriedok s ich obsahom a ich použitie |
JP2005505595A (ja) * | 2001-10-12 | 2005-02-24 | シェーリング コーポレイション | Cxc−ケモカインレセプターアンタゴニストとしての3,4−二置換マレイミド化合物 |
US6878709B2 (en) * | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
CA2479126C (en) * | 2002-03-18 | 2011-11-15 | Schering Corporation | Combination treatments for chemokine-mediated diseases |
ATE422203T1 (de) * | 2002-10-09 | 2009-02-15 | Schering Corp | Thiadiazoldioxide und thiadiazoloxide als cxc- und cc-chemokinrezeptor liganden |
-
2007
- 2007-07-05 AR ARP070103000A patent/AR061829A1/es not_active Application Discontinuation
- 2007-07-05 WO PCT/US2007/015671 patent/WO2008005570A1/en active Application Filing
- 2007-07-05 PE PE2007000871A patent/PE20080553A1/es not_active Application Discontinuation
- 2007-07-05 CN CNA2007800327026A patent/CN101511809A/zh active Pending
- 2007-07-05 AU AU2007269572A patent/AU2007269572A1/en not_active Abandoned
- 2007-07-05 TW TW096124499A patent/TW200813033A/zh unknown
- 2007-07-05 US US11/773,479 patent/US20080045489A1/en not_active Abandoned
- 2007-07-05 JP JP2009518399A patent/JP2009542700A/ja not_active Withdrawn
- 2007-07-05 BR BRPI0713559-9A patent/BRPI0713559A2/pt not_active IP Right Cessation
- 2007-07-05 MX MX2009000123A patent/MX2009000123A/es unknown
- 2007-07-05 CL CL2007001969A patent/CL2007001969A1/es unknown
- 2007-07-05 CA CA002657051A patent/CA2657051A1/en not_active Abandoned
- 2007-07-05 KR KR1020097002397A patent/KR20090028811A/ko not_active Application Discontinuation
- 2007-07-05 RU RU2009103999/04A patent/RU2009103999A/ru not_active Application Discontinuation
- 2007-07-05 EP EP07810279A patent/EP2041107A1/en not_active Withdrawn
-
2009
- 2009-01-01 IL IL196335A patent/IL196335A0/en unknown
- 2009-01-06 ZA ZA200900110A patent/ZA200900110B/xx unknown
- 2009-01-08 EC EC2009009042A patent/ECSP099042A/es unknown
- 2009-02-06 NO NO20090594A patent/NO20090594L/no not_active Application Discontinuation
- 2009-02-06 CO CO09011530A patent/CO6150138A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20080553A1 (es) | 2008-05-16 |
AR061829A1 (es) | 2008-09-24 |
KR20090028811A (ko) | 2009-03-19 |
MX2009000123A (es) | 2009-03-25 |
BRPI0713559A2 (pt) | 2012-03-13 |
ZA200900110B (en) | 2010-09-29 |
WO2008005570A1 (en) | 2008-01-10 |
CA2657051A1 (en) | 2008-01-10 |
CO6150138A2 (es) | 2010-04-20 |
IL196335A0 (en) | 2009-09-22 |
JP2009542700A (ja) | 2009-12-03 |
AU2007269572A1 (en) | 2008-01-10 |
EP2041107A1 (en) | 2009-04-01 |
ECSP099042A (es) | 2009-02-27 |
TW200813033A (en) | 2008-03-16 |
US20080045489A1 (en) | 2008-02-21 |
CL2007001969A1 (es) | 2008-01-18 |
RU2009103999A (ru) | 2010-08-20 |
CN101511809A (zh) | 2009-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20090594L (no) | 3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander | |
Wells et al. | 4-Substituted 4-hydroxycyclohexa-2, 5-dien-1-ones with selective activities against colon and renal cancer cell lines | |
AP1122A (en) | Therapeutically active compounds based on based on based on indazole bioisostere replacement of catechol in PDE4 inhibitors. | |
NO20051036L (no) | 3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander | |
Hsieh et al. | Antrocamphin A, an anti-inflammatory principal from the fruiting body of Taiwanofungus camphoratus, and its mechanisms | |
Kuo et al. | Anti-inflammatory diterpenoids from Croton tonkinensis | |
Ma et al. | Structural investigation and biological activity of sesquiterpene lactones from the traditional Chinese herb Inula racemosa | |
NO20070076L (no) | Nye indazolkarboksamider og deres anvendelse | |
NO20076561L (no) | Imidazoquinoliner som lipid kinaseinhibitorer | |
NO20084603L (no) | Dialkylfenylforbindelser som har beta2 adrenergisk reseptoragonist- og muskarin reseptoragonistaktivitet | |
Peng et al. | Rational design, synthesis, and pharmacological properties of pyranochalcone derivatives as potent anti-inflammatory agents | |
AU2015336458A1 (en) | KCNQ2-5 channel activator | |
Abdellatif et al. | New 1, 2-diaryl-4-substituted-benzylidene-5-4H-imidazolone derivatives: Design, synthesis and biological evaluation as potential anti-inflammatory and analgesic agents | |
Gaines et al. | Synthesis and evaluation of 2, 5 and 2, 6 pyridine-based CXCR4 inhibitors | |
Kumar et al. | Synthesis of some newer derivatives of 2-amino benzoic acid as potent anti-inflammatory and analgesic agents | |
Hasan et al. | Synthesis of new Diclofenac derivatives by coupling with chalcone derivatives as possible mutual prodrugs | |
Lin et al. | Selective COX-2 inhibitors. Part 2: Synthesis and biological evaluation of 4-benzylideneamino-and 4-phenyliminomethyl-benzenesulfonamides | |
Weng et al. | Anti-inflammatory Constituents and New Pterocarpanoid of Crotalaria p allida | |
Chen et al. | Synthesis and biological evaluation of novel indole-2-one and 7-aza-2-oxindole derivatives as anti-inflammatory agents | |
Zhuang et al. | Copper-Catalyzed Oxidative C (sp3)–H/C (sp3)–H Cross-Coupling Reaction of 3-Methylbenzo [c] isoxazoles with Methyl Ketones: Access to Indigoid Analogues | |
US10385034B2 (en) | Flavonoid IL-17A inhibitors | |
Kumar et al. | Total Synthesis of Two Glycosylated Stilbenes, Oxyresveratrol 2-O-β-d-Glucopyranoside and 2, 3, 5, 4′-Tetrahydroxystilbene 2-O-β-d-Glucopyranoside | |
Rai et al. | Synthesis of Some Novel 2‐[2‐(aroyl‐aroxy)‐methyl]‐4‐phenyl‐1, 3‐thiazoles as Potent Anti‐Inflammatory Agents | |
Wang et al. | Design, Synthesis, and Apoptosis-Promoting Effect Evaluation of Chalcone Derivatives Containing Aminoguanidine Units | |
Zhang et al. | Identification of chalcone analogues as anti-inflammatory agents through the regulation of NF-κB and JNK activation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |